Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03590327 · ClinicalTrials.gov registry record · NA

Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
103
Enrollment target

NCT03590327: Completed NA study, sponsored by VA Office of Research and Development.

NCT03590327 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 103 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03590327, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
103 participants
Enrollment target

Study Summary

Apathy, a profound loss of initiative and motivation, is often seen in older Veterans with memory problems. Apathy leads to serious health problems, increases dependency, and caregiver burden. If untreated, apathy hastens the progression to frank dementia. In a pilot study, the investigators found that apathy, working memory, and function can be restored using magnetic stimulation in some but not all older Veterans. The reason for this variation is unknown. The investigators propose a three-phase study in 125 older Veterans with mild memory problems. Their motivation, memory, and function will be measured periodically. Veterans with apathy that are eligible for treatment will receive either real or sham magnetic stimulation to the front part of their brain over 20 sessions. Genetic testing and biomarkers will be used to differentiate those who respond to magnetic stimulation from those who do not. Impact on function, quality of life, and rates of progression to dementia will also be studied. A project modification was obtained to conduct a cross-sectional study, the COVID Dementia study. The cross-sectional study will examine the effect of the pandemic on MCI and AD patients and their caregivers ("individual COVID-related factors" such as, personally infected, death of a friend/family member, economic hardship, disruption in care, isolation), barriers to telehealth, caregiver distress, NPS, cognition (including onset of delirium), and function. Our goal is to develop a multi-pronged, remotely deliverable intervention to address consequences of healthcare disruptions in older Veterans with cognitive impairment. Aim 1. To explore the association between COVID-related factors and neuropsychiatric symptoms in individuals with MCI and AD. Hypothesis: The number of COVID-related factors endorsed by caregivers will be positively correlated with the severity of NPI-Q in individuals with MCI and AD. Aim 2. To assess cognition (telephonic version of the Montreal Cognitive

Primary Outcome

Range 18-72 Lower score is improvement

Interventions

  • DEVICE Transcranial Magnetic Stimulation

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2018-11-01
Est. Completion 2024-10-31
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT03590327 record still lists

NCT03590327 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 1 intervention - of which Transcranial Magnetic Stimulation is the first listed.

NCT03590327 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03590327 about?

NCT03590327 is a clinical study titled "Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment". Apathy, a profound loss of initiative and motivation, is often seen in older Veterans with memory problems. Apathy leads to serious health problems, increases dependency, and caregiver burden. If untreated, apathy hastens the progression to frank dementia. In a pilot study, the investigators found t...

What is the current status of trial NCT03590327?

This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2018-11-01. Estimated completion is 2024-10-31.

What interventions are being tested in trial NCT03590327?

The interventions under investigation include: Transcranial Magnetic Stimulation (DEVICE).

Who is sponsoring clinical trial NCT03590327?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03590327's enrollment target sits among peer trials

103 837th of 2000 higher than 1,164 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03590327, the US trial registry maintained by the National Library of Medicine. NCT03590327 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.